Medtronic (MDT) announced positive clinical outcomes from two studies in atrial fibrillation, AFib, patients treated with the Affera family of technologies, including the next-generation Sphere-360 single-shot pulsed field ablation catheter and the groundbreaking Sphere-9 combination mapping and dual-energy focal PFA catheter. Data were presented in High Impact Science Sessions at the Heart Rhythm Society 2025 Annual Meeting in San Diego; the Sphere-360 study was simultaneously published in the Heart Rhythm Journal. The company said; One-year clinical trial data for the next-generation, investigational, Sphere-360 single-shot PFA catheter show impressive safety, performance, and efficiency results for paroxysmal Afib; Dual-energy, focal Sphere-9 catheter demonstrates efficacy for linear ablation in persistent AFib; Medtronic continues legacy of leadership in innovation, showcasing arrhythmia management portfolio at Heart Rhythm Society annual meeting
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic receives FDA approval for OmniaSecure defibrillation lead
- China weighing exemption of some U.S. goods from tariffs, Bloomberg reports
- Medtronic submits application to FDA for interoperable insulin pump
- Medtronic price target lowered to $90 from $93 at Truist
- Medtronic put volume heavy and directionally bearish
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue